Abstract
Introduction
Despite recent advances in medical and device therapy, ischemic heart failure remains one of the leading causes of morbidity and mortality worldwide. In the United States alone, it has been estimated that 5.7 million people are currently suffering with heart failure, resulting in healthcare costs of $37.2 billion [1] . Ischemic heart failure is a complex chronic syndrome which is characterized by both structural and functional changes in both the infarcted and the non-infarcted remote myocardium. In response to a myocardial infarction (MI) , the heart undergoes a complex intrinsic reparative process of ventricle remodelling which results in collagen scar tissue formation in the infarcted myocardium, and hypertrophy and fibrosis of the non-infarcted myocardium, resulting in ventricular dilatation, contractile dysfunction and subsequent heart failure [2, 3] . Therefore, novel treatment strategies that are capable of limiting myocardial infarct size, preventing adverse left ventricular (LV) remodelling and preserving LV systolic function are required to improve clinical outcome in this patient group.
In this respect, the mitochondrial permeability transition pore (mPTP), a critical mediator of cell death, has emerged as an important therapeutic target for limiting acute ischemia-reperfusion injury. The genetic ablation [4, 5] and pharmacological inhibition [6] [7] [8] [9, 10] . Whether targeted inhibition of mitochondrial CypD is also beneficial in non-reperfused post-MI heart failure is currently unknown. -/-were generated as previously described [4] . 
of mitochondrial cyclophilin-D (CypD), a key regulatory component of the mPTP, has been reported to reduce myocardial infarct size in animal studies. However, it must be appreciated that CypDdeficient hearts are still susceptible to mPTP opening induced through mechanisms which are independent of CypD. More recently, cyclosporin-A (CsA), a pharmacological inhibitor of CypD has been reported to limit myocardial infarct size and improve LV function in ST-elevation MI patients undergoing primary percutaneous coronary intervention when given at reperfusion

Materials and methods
A detailed
Murine model of myocardial infarction
Magnetic resonance imaging (MRI)
Western blot analysis of myocardial apoptosis
Cardiac fibroblast isolation and proliferation assay
Cardiac fibroblasts were isolated from WT and CypD -/-mice using a modification of a previously published method [11] (Fig. 2D ). (Fig. 5C ). (Fig. 6A) (Fig. 6B) .
Results
Mortality following myocardial infarction
Myocardial apoptosis
Ex vivo cardiac fibroblast proliferation
Cardiac fibroblasts isolated from WT and CypD -/-mice were identified by DDR2 immunostaining, and demonstrated to co-localize with wheat germ agglutinin
Discussion
The major finding of the present study is that the heart deficient in mitochondrial CypD is more resistant to the detrimental effects of heart failure following an MI. Following [13, 14] and in phenylephrine-induced neonatal cardiomyocyte hypertrophy [15] . Furthermore, CsA has been reported to preserve mitochondrial morphology in the heart following ischemia [16] . However, as well as inhibiting CypD, CsA also inhibits other cyclophilins and calcineurin. The inhibition of calcineurin-mediated dephosphorylation of the apoptogenic protein Bcl-2-associated death promoter (BAD) can, in itself, result in cardioprotection [17] . In addition, calcineurin inhibition has been recently demonstrated to inhibit mitochondrial fragmentation which may also have cytoprotective effects [18] . Deletion of the CypD gene has been shown to prevent heart failure caused by doxorubicin-induced cardiotoxicity, or as a result of calcium dysregulation by the overexpression of the ␤2a subunit of L-type calcium channels [19] . However, the role of CypD in the setting of post-MI heart failure has not been previously investigated.
In the present study, WT mice had a post-MI mortality of 56%, and this was found to occur within the time window of 3 to 5 days after MI and appeared due to infarct rupture. Our findings concur with previous studies implicating infarct rupture occurring in response to reduced tensile strength of the infarcted myocardium as a major cause of mortality [20] [21] [22] [26] . Apoptosis is known to contribute to the progression of heart failure following an MI [24, [27] [28] [29] , but the role of the mPTP as a mediator of apoptotic cell death is controversial [4, 5, 16, [30] [31] [32] [19] . Interestingly, in some previous non-cardiac studies [34, 35] 
